Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Watkins
Scikon Innovation, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
University of North Carolina at Chapel Hill
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
New document uploaded as attachment (no changes from previous FCOI document); referencing the previously approved FCOI in 2017
Standardization of a Fluidic In Vitro Exposure System for IVIVE Predictive Toxicity Data
Narrative Standardization of a Fluidic In vitro Exposure System for IVIVE Predictive Toxicity Data The high failure rate of drugs in late stage clinical development is an indication that nonclinical in vitro and pre- clinical animal models consistently fail to accurately predict compound efficacy and toxicity in the human body. This is because currently available static tissue culture systems and animal testing often fail to adequately reproduce human physiology and to identify dangerous compounds, resulting in expensive late stage compound failures. We have developed the SciFlow 1000, a 96 well microfluidic tissue culture system that incorporates fluid movement with compound and metabolite exposure gradients into a benchtop model that when combined with liver cells, produces a superior model of human physiology and mimics compound exposure in the human liver. This Phase II application outlines the optimization of compound dosing and assays, with the goal of developing a well-validated method for predicting drug-induced liver injury that leverages the unique benefits of the SciFlow 1000.
Filed on July 12, 2018.
Tell us what you know about Paul Watkins's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Paul Watkins”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Watkins | Scikon Innovation, Inc. | Conflict of Interest | DILIsym Services Inc | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.